Chimeric FVIII Purification Using Affinity and AEX Chromatography

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The purification of recombinant factor VIII (FVIII) is challenging due to low expression levels and sensitivity to pH and temperature changes, necessitating improved methods to obtain highly active FVIII.

Innovation Solution

A novel purification method combining protein-specific affinity chromatography, such as VIIISelect, followed by anion exchange chromatography, is employed to purify chimeric FVIII proteins.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional purification methods are used, then the process is simpler, but the purity and activity of recombinant FVIII are insufficient

Engineering Contradiction:

Improvepurity and activity of recombinant FVIIIVSAvoidpurification process complexity

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The purification process is divided into multiple sequential steps: (i) affinity chromatography to capture FVIII from complex media, (ii) ion exchange chromatography for further purification, and (iii) size exclusion chromatography for final polishing. Each step targets specific impurities and progressively enhances purity while maintaining activity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces VWF (von Willebrand Factor) as an intermediary molecule to facilitate purification. FVIII is expressed as a complex with VWF, which serves as a protective carrier through the purification process and is subsequently removed, yielding highly active FVIII.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If expression levels are increased, then more FVIII is produced, but the sensitivity to pH and temperature changes causes degradation

Engineering Contradiction:

Improveexpression level of FVIIIVSAvoidstability of FVIII

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

VWF acts as a protective intermediary that stabilizes FVIII during high-level expression and purification. The FVIII-VWF complex protects FVIII from pH and temperature sensitivity, allowing robust production followed by controlled dissociation to yield active FVIII.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The purification process employs carefully controlled parameter changes, including pH gradients in ion exchange chromatography and temperature control throughout the process, to maintain FVIII stability while enabling high-level expression and effective purification.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method yields highly active recombinant FVIII, overcoming the limitations of existing purification techniques by enhancing the purity and activity of the protein.

Implementation Method 1

subjecting the conditioned media comprising the chimeric protein to a factor VIII-specific affinity chromatography matrix

Methodology Applied

Scientific EffectAffinity chromatography: Chromatography

Implementation Method 2

subjecting the chimeric protein to an anion exchange (AEX) chromatography resin

Methodology Applied

Scientific EffectAnion exchange chromatography: Chromatography

Data Source

PatentUS12570691B2Purification of chimeric FVIII molecules

Publication Date: 2026.03.10 BIOVERATIV THERAPEUTICS INC

AI summary

The invention is directed to methods of purifying a chimeric protein comprising subjecting the chimeric protein to a factor VIII-specific affinity chromatography, and subjecting the chimeric protein to an AEX chromatography; wherein the chimeric protein comprises a factor VIII protein or a fragment thereof. The chimeric protein purified by the present methods shows improved factor VIII activity.